Bausch + Lomb to Showcase 14 Scientific Data Presentations at Optometry’s Meeting® 2026, Including an AOA Top Five Presentation

  • A live presentation on XIIDRA® (lifitegrast ophthalmic solution) 5% has been named an AOA Top Five Presentation, marking the fourth consecutive year Bausch + Lomb has received this recognition
  • Thirteen poster presentations will highlight data across consumer eye care products, contact lenses and pharmaceuticals
  • Expert-led educational programs will focus on dry eye management and clinical care, featuring select Bausch + Lomb products

VAUGHAN, Ontario, June 10, 2026 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced one live presentation and 13 poster presentations at Optometry’s Meeting, the annual American Optometric Association (AOA) Congress, taking place in Phoenix, Arizona, June 17–20, 2026. The company will also host several educational events during the meeting.

The live presentation, which will explore treatment response patterns in dry eye disease with XIIDRA was recognized by the AOA as a Top Five Presentation – the fourth consecutive year a Bausch + Lomb presentation has been selected for this distinction.

The poster presentations will highlight data across the company’s eye health portfolio, including consumer eye care products, contact lenses and pharmaceuticals. Featured brands include new PreserVision AREDS3™ eye vitamins, LUMIFY® redness reliever eye drops and Blink™ NutriTears clinically proven supplement for dry eyes*; Bausch + Lomb INFUSE®, Bausch + Lomb ULTRA® and Biotrue® ONEday contact lenses; as well as MIEBO® (perfluorohexyloctane ophthalmic solution), VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% and XIIDRA.

Sponsored educational events will focus on topics such as dry eye management and feature products including PreserVision AREDS3, Blink® Triple Care Preservative Free eye drops, MIEBO and XIIDRA.

Below is a complete list of events and presentations.

Live Presentation

  • “Patterns of Response to Treatment with Lifitegrast Ophthalmic Solution in Patients with Dry Eye Disease.” Tichenor A.

Poster Presentations

  • “A Meta-Analysis of the Safety of Nesofilcon A Soft Daily Disposable Hydrogel Contact Lenses.” Hoffman K.
  • “A Phase 3 Randomized Trial of a Novel Hyaluronate-Containing Formulation of Brimonidine Tartrate Ophthalmic Solution for the Treatment of Conjunctival Hyperemia.” Kannarr S.
  • “Assessment of a Novel Formulation of Brimonidine Tartrate Ophthalmic Solution Containing Hyaluronic Acid Over Four Weeks of Use.” Lang J.
  • “Comparative Analysis of AREDS2 and AREDS2+B Vitamin Complex in an in vitro Model of Age-Related Macular Degeneration.” Christie L.
  • “Concomitant Use of Perfluorohexyloctane and Lifitegrast in Dry Eye Disease Management: Results from a Nationwide Survey of Eyecare Providers.” Quint J.
  • “Lifitegrast Ophthalmic Solution in Patients with Dry Eye Disease: Real-World Evidence from a Provider Survey and a Pharmacovigilance Database.” Barnett M.
  • “Patient-Reported Outcomes with a Novel Daily Disposable Toric Contact Lens in Dryness Sufferers.” Brujic M.
  • “Real-World Characteristics of Patients with Autoimmune Diseases Receiving Dry Eye Disease Treatment with Lifitegrast: A Retrospective Registry-Based Cohort Study.” Kannarr S.
  • “Real-World Evidence on Patient and Eyecare Provider Satisfaction with Latanoprostene Bunod 0.024% for Open-Angle Glaucoma and Ocular Hypertension.” Koetting C.
  • “Real-World Insights for Patients Transitioning from Monovision to Monthly Multifocal Toric Lenses.” Hoffman K.
  • “Real-World Insights into Patients Transitioning from Frequent Replacement Lenses to Nesofilcon A Daily Disposable Lenses.” Hoffman K.
  • “Real-World Use of a Nutritional Supplement to Help Relieve Dry Eye: A 56-Day In-Home Usage Study.” Gioia N.
  • “Use of Perfluorohexyloctane Ophthalmic Solution Before and After Cataract Surgery in Patients with Dry Eye Disease.” Schweitzer J.

Educational Events
Thursday, June 18
Fast Tracking Dry Eye Management: Integrating Science and Practice

  • 8:00-9:00 am. PT; Phoenix Convention Center, 100 North Third Street, Room: 129 AB
  • Speakers: Mila Ioussifova, OD, FAAO; Vin T. Dang, OD, FAAO
     

A Family of Eye Care Products with Innovations at Every Stage of Life

  • 12:00-1:00 p.m. PT; Phoenix Convention Center, 100 North Third Street, Room: 131 ABC
  • Speakers: Mile Brujic, OD, FAAO; Mark Schaeffer, OD, FAAO
     

Friday, June 19
The Puzzle of Dry Eye: Targeted Approaches to a Multifactorial Condition

  • 8:00-9:00 a.m. PT; Phoenix Convention Center, 100 North Third Street, Room: 129 AB
  • Speakers: Cecelia Koetting, OD, FAAO, DipABO; Walter Whitley, OD, FAAO

Saturday, June 20
PreserVision AREDS3: An Updated Nutrient Formula Inspired by Scientific Evidence

  • 8:00-9:00 a.m. PT; Phoenix Convention Center, 100 North Third Street, Room: 129 AB
  • Speaker: Jeffry Gerson, OD, FAAO
     

OTC Eye drops: More Than Meets the Eye

  • 12:00-1:00 p.m. PT; Phoenix Convention Center, 100 North Third Street; Room: 129 AB
  • Speaker: Cecilia Koetting, OD, FAAO, DipABO
     

###

XIIDRA Indications and Important Safety Information

Indication
Xiidra (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.


Click here for full Prescribing Information for Xiidra.

MIEBO Indications and Important Safety Information

Indication
MIEBO (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

Important Safety Information

  • MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane
  • MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO
  • Instruct patients to instill one drop of MIEBO into each eye four times daily
  • The safety and efficacy in pediatric patients below the age of 18 have not been established
  • In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)
     

Click here for full Prescribing Information for MIEBO.

VYZULTA Indications and Important Safety Information

INDICATION
VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)

Please click here to see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

###
 

About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com  and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.


*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
 


©2026 Bausch + Lomb.
MTB.0229.USA.26

Media Contact:
Kristy Marks
[email protected]
(908) 927-0683

Back to Press Releases